Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778740 | 0.90 | HPGD (0.37) | HPGDL3MBTL1ALDH1A1NPC1MAPT | |
| SCHEMBL3779072 | 0.87 | LMNA (0.37) | HPGDL3MBTL1ALDH1A1MAPTKDM4E | |
| SCHEMBL2571353 | 0.85 | HPGD (0.34) | HPGDALDH1A1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2570600 | 0.85 | LMNA (0.33) | HPGDALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL534098 | 0.83 | ALDH1A1 (0.34) | HPGDALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL3777589 | 0.83 | TSHR (0.40) | HPGDL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL3780979 | 0.83 | HPGD (0.40) | HPGDL3MBTL1NPY4RHSD17B10 | |
| SCHEMBL2573441 | 0.80 | PTGDR2 (0.46) | KDM4E | |
| SCHEMBL3779428 | 0.79 | PTGDR2 (0.36) | HPGDALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL534053 | 0.77 | MAOB (0.34) | ALDH1A1MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | HPGD 1772/4885L3MBTL1 3442/4885ALDH1A1 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.